文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

微生物胆汁盐水解酶介导粪菌移植治疗复发性感染的疗效。

Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection.

机构信息

Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.

Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

Gut. 2019 Oct;68(10):1791-1800. doi: 10.1136/gutjnl-2018-317842. Epub 2019 Feb 11.


DOI:10.1136/gutjnl-2018-317842
PMID:30816855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6839797/
Abstract

OBJECTIVE: Faecal microbiota transplant (FMT) effectively treats recurrent infection (rCDI), but its mechanisms of action remain poorly defined. Certain bile acids affect germination or vegetative growth. We hypothesised that loss of gut microbiota-derived bile salt hydrolases (BSHs) predisposes to CDI by perturbing gut bile metabolism, and that BSH restitution is a key mediator of FMT's efficacy in treating the condition. DESIGN: Using stool collected from patients and donors pre-FMT/post-FMT for rCDI, we performed 16S rRNA gene sequencing, ultra performance liquid chromatography mass spectrometry (UPLC-MS) bile acid profiling, BSH activity measurement, and qPCR of /CD genes involved in bile metabolism. Human data were validated in batch cultures and a C57BL/6 mouse model of rCDI. RESULTS: From metataxonomics, pre-FMT stool demonstrated a reduced proportion of BSH-producing bacterial species compared with donors/post-FMT. Pre-FMT stool was enriched in taurocholic acid (TCA, a potent germinant); TCA levels negatively correlated with key bacterial genera containing BSH-producing organisms. Post-FMT samples demonstrated recovered BSH activity and /CD gene copy number compared with pretreatment (p<0.05). In batch cultures, supernatant from engineered -expressing and naturally BSH-producing organisms ( and ) reduced TCA-mediated germination relative to culture supernatant of wild-type (BSH-negative) total viable counts were ~70% reduced in an rCDI mouse model after administration of expressing highly active BSH relative to mice administered BSH-negative (p<0.05). CONCLUSION: Restoration of gut BSH functionality contributes to the efficacy of FMT in treating rCDI.

摘要

目的:粪便微生物群移植(FMT)有效地治疗复发性感染(rCDI),但其作用机制仍未明确定义。某些胆汁酸会影响发芽或营养生长。我们假设肠道微生物群衍生的胆盐水解酶(BSH)的丧失会通过扰乱肠道胆汁代谢而导致 CDI,并且 BSH 的恢复是 FMT 治疗该疾病疗效的关键介质。

设计:使用来自患者和供体 rCDI 治疗前/后的粪便进行 16S rRNA 基因测序、超高效液相色谱-质谱(UPLC-MS)胆汁酸分析、BSH 活性测定以及涉及胆汁代谢的 /CD 基因的 qPCR。人类数据在批培养和 rCDI 的 C57BL/6 小鼠模型中得到了验证。

结果:从宏基因组学分析来看,rCDI 治疗前的粪便中与供体/治疗后的粪便相比,产生 BSH 的细菌种类比例降低。rCDI 治疗前的粪便中富含牛磺胆酸(TCA,一种有效的发芽剂);TCA 水平与含有 BSH 产生菌的关键细菌属呈负相关。与治疗前相比,治疗后的样本显示 BSH 活性和 /CD 基因拷贝数得到恢复(p<0.05)。在批培养中,表达的 和天然产生 BSH 的 ( 和 )的上清液可降低 TCA 介导的 发芽,与野生型(BSH 阴性)的培养上清液相比,rCDI 小鼠模型中表达高活性 BSH 的 给药后 TCA 介导的 发芽率降低了约 70%,而给予 BSH 阴性 的小鼠则降低了(p<0.05)。

结论:肠道 BSH 功能的恢复有助于 FMT 治疗 rCDI 的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/cc2aa7646a2b/gutjnl-2018-317842f07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/6af768a76937/gutjnl-2018-317842f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/d8ad7e01afb1/gutjnl-2018-317842f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/a4a7286d5f2c/gutjnl-2018-317842f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/727753ed54dc/gutjnl-2018-317842f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/06572f1263e2/gutjnl-2018-317842f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/83865a428744/gutjnl-2018-317842f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/cc2aa7646a2b/gutjnl-2018-317842f07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/6af768a76937/gutjnl-2018-317842f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/d8ad7e01afb1/gutjnl-2018-317842f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/a4a7286d5f2c/gutjnl-2018-317842f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/727753ed54dc/gutjnl-2018-317842f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/06572f1263e2/gutjnl-2018-317842f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/83865a428744/gutjnl-2018-317842f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b2/6839797/cc2aa7646a2b/gutjnl-2018-317842f07.jpg

相似文献

[1]
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection.

Gut. 2019-2-11

[2]
Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent infection.

mSphere. 2024-10-29

[3]
Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.

Gastroenterology. 2018-7-17

[4]
The presence of Clostridioides difficile in faeces before and after faecal microbiota transplantation and its relation with recurrent C. difficile infection and the gut microbiota in a Dutch cohort.

Clin Microbiol Infect. 2025-4

[5]
Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.

Gut Microbes. 2018-9-5

[6]
Longitudinal Bile Acid Composition Changes Following Faecal Microbiota Transplantation for Clostridioides difficile Infection in Children With and Without Underlying Inflammatory Bowel Disease.

J Crohns Colitis. 2023-8-21

[7]
Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.

BMC Gastroenterol. 2018-8-28

[8]
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).

Cochrane Database Syst Rev. 2023-4-25

[9]
Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent infection and beyond: the contribution of gut microbial-derived metabolites.

Gut Microbes. 2020-11-9

[10]
BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection.

PLoS One. 2018-5-8

引用本文的文献

[1]
Effect of fecal microbiota transplantation on gut microbiota functional profile in recipients of allogeneic hematopoietic cell transplantation.

Gut Microbes. 2025-12

[2]
Fecal bile acid profiles before and after fecal microbial transplant in pediatric onset ulcerative colitis.

Gut Microbes Rep. 2024

[3]
Host origin of microbiota drives functional recovery and clearance in mice.

mBio. 2025-6-2

[4]
Growth curve fitting and analysis of intestinal flora changes of the Magang Goose (Anser domesticus) during 1 to 70 days post hatch.

Poult Sci. 2025-5-5

[5]
Targeting Bile-Acid Metabolism: Nutritional and Microbial Approaches to Alleviate Ulcerative Colitis.

Nutrients. 2025-3-28

[6]
Nonobstructive Recurrent Cholangitis After Hepatobiliary Tract Diversion in Patients With Surgically Altered Anatomy: A Challenging Problem.

ACG Case Rep J. 2025-3-5

[7]
A designed synthetic microbiota provides insight to community function in Clostridioides difficile resistance.

Cell Host Microbe. 2025-3-12

[8]
New insights into microbial bile salt hydrolases: from physiological roles to potential applications.

Front Microbiol. 2025-2-12

[9]
Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease.

Liver Res. 2023-9-11

[10]
infection study models and prospectives for probing the microbe-host interface.

J Bacteriol. 2025-3-20

本文引用的文献

[1]
Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation.

Microbiome. 2018-12-10

[2]
Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.

Gut Microbes. 2018-9-5

[3]
The use of faecal microbiota transplant as treatment for recurrent or refractory infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Gut. 2018-8-28

[4]
Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.

BMC Gastroenterol. 2018-8-28

[5]
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.

Gastroenterology. 2018-8-23

[6]
Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.

Gastroenterology. 2018-7-17

[7]
BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection.

PLoS One. 2018-5-8

[8]
Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease.

Methods. 2018-4-26

[9]
Clostridium scindens Is Present in the Gut Microbiota during Clostridium difficile Infection: a Metagenomic and Culturomic Analysis.

J Clin Microbiol. 2018-4-25

[10]
Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

JAMA. 2017-11-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索